Improved Insulin Sensitivity in 51 Nondiabetic Depressed Inpatients Remitting During Antidepressive Treatment With Mirtazapine and Venlafaxine

Weber-Hamann, Bettina; Gilles, Maria; Schilling, Cláudia; Onken, Vera; Frankhauser, Pascal; Kopf, Daniel; Lederbogen, Florian; Deuschle, Michael

doi:10.1097/jcp.0b013e31818582ef

Cited by 26 publications

(24 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The existing literature suggests that depression remission rather than depression treatment per se is associated with improved Si. Two depression treatment studies in nondiabetics found improved insulin sensitivity with depression remission with different antidepressants including mirtazapine, venlafaxine [12], amitriptyline, and paroxetine. [12].…”

Section: Discussionmentioning

confidence: 99%

“…Studies of clinical samples have found lower levels of insulin sensitivity in depressed patients than their age-, sex-, and body mass index-matched controls [15]. Furthermore, some data suggest that insulin resistance improves with depression treatment and/or remission in nondiabetics [9, 11, 12], and that glycemic control improves with depression remission in persons with diabetes. [13]…”

Section: Introductionmentioning

confidence: 99%

“…A handful of depression treatment studies show benefit for Si with depression remission, suggesting that resolving the depression disorder, or depression treatment per se, positively impacts Si [9, 11, 12]. However, secondary analysis of DPP data [20], as well as a recent large observational study [26] suggest that antidepressant medication may actually increase risk for diabetes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes

Wagner

Allen

Swalley

et al. 2009

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Aims-To compare insulin sensitivity (Si) in adults at risk for type 2 diabetes (T2DM) who were categorized as non-depressed, treated for depression and untreated depression after controlling for PA (PA).Methods-Baseline data was analyzed from individuals enrolled in a diabetes prevention program (n=56). Si was calculated using the whole body insulin sensitivity method. The Centers for Epidemiologic Studies Depression Scale (CESD) was used to assess depressive symptoms and depressed cases were identified using a cutoff of ≥16. Depression treatment was identified using a self-report form validated by medical chart review. The PA subscale of the Health Promoting Lifestyle Profile was used to determine PA levels.Results-One third of participants had elevated depressive symptoms; 19% were taking antidepressant medication. Mean Si was 3.0 (±1.9). In ANOVA, depressed individuals (M=1.79 ±0.91) showed significantly lower Si than non-depressed individuals (M=3.39±1.78). However, individuals taking antidepressant medications had Si similar to non-depressed individuals (M=3.10 ±1.86: p=.63). In ANCOVA this association remained after controlling for PA.Conclusions-These data suggest that in adults at high risk for T2DM, depression treatment may improve insulin resistance observed in depression. Healthcare practitioners are encouraged to screen, treat, or refer their patients with depression for treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes

Wagner

Allen

Swalley

et al. 2009

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…However, diabetes and “pre-diabetes” (impaired glucose tolerance and impaired fasting glucose) are diagnosed only by measured hyperglycemia (American Diabetes Association, 2013). Of note, some depressed individuals manifest insulin resistance (Nathan et al, 1981; Menna-Perper et al, 1984; Winokur et al, 1988; Okamura et al, 2000; Hennings et al, 2010) which improves with depression treatment (Nathan et al, 1981; Okamura et al, 2000; Hennings et al, 2010; Mueller et al, 1969; Weber-Hamann et al, 2008). …”

Section: Introductionmentioning

confidence: 99%

The relationship between fasting serum glucose and cerebral glucose metabolism in late-life depression and normal aging

Marano

Workman

Lyman

et al. 2014

Psychiatry Research: Neuroimaging

View full text Add to dashboard Cite

Evidence exists for late-life depression (LLD) as both a prodrome of and risk factor for Alzheimer’s disease (AD). The underlying neurobiological mechanisms are poorly understood. Impaired peripheral glucose metabolism may explain the association between depression and AD given the connection between type 2 diabetes mellitus with both depression and AD. Positron emission tomography (PET) measures of cerebral glucose metabolism are sensitive to detecting changes in neural circuitry in LLD and AD. Fasting serum glucose (FSG) in non-diabetic young (YC; n=20) and elderly controls (EC; n=12) and LLD patients (n=16) was correlated with PET scans of cerebral glucose metabolism on a voxel-wise basis. The negative correlations were more extensive in EC versus YC and in LLD patients versus EC. Increased FSG correlated with decreased cerebral glucose metabolism in LLD patients to a greater extent than in EC in heteromodal association cortices involved in mood symptoms and cognitive deficits observed in LLD and dementia. Negative correlations in YC were observed in sensory and motor regions. Understanding the neurobiological consequences of diabetes and associated conditions will have substantial public health significance given that this is a modifiable risk factor for which prevention strategies could have an important impact on lowering dementia risk.

show abstract

“…Accordingly, glucose tolerance improves in patients remitting under treatment with amitriptyline [3] and mirtazapine [4] , since both drugs lead to lowered saliva and urinary cortisol [5,6] . Interestingly, we also found improved glucose tolerance in depressed patients responding to paroxetine and venlafaxine treatment [3,7] , although saliva cortisol concentrations did not decline [5 ; unpubl. obs.].…”

mentioning

confidence: 99%

Venlafaxine, but Not Mirtazapine Lowers Retinol-Binding Protein 4 Serum Concentrations in Nondiabetic Depressed Patients

Deuschle

Angermeier

Westphal

et al. 2010

Psychother Psychosom

View full text Add to dashboard Cite

Improved Insulin Sensitivity in 51 Nondiabetic Depressed Inpatients Remitting During Antidepressive Treatment With Mirtazapine and Venlafaxine

Cited by 26 publications

References 8 publications

Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes

Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes

The relationship between fasting serum glucose and cerebral glucose metabolism in late-life depression and normal aging

Venlafaxine, but Not Mirtazapine Lowers Retinol-Binding Protein 4 Serum Concentrations in Nondiabetic Depressed Patients

Contact Info

Product

Resources

About